Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 17/20 | 0.49 |
| ▸ | FNTB | P49356 | 17/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 14/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893197 | 0.88 | FNTA (0.45) | FNTAFNTBPGGT1BCKS1BSKP1 | |
| SCHEMBL4897561 | 0.86 | FNTA (0.53) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL452165 | 0.84 | FNTA (0.46) | FNTAFNTBPGGT1B | |
| SCHEMBL4896990 | 0.81 | FNTA (0.50) | FNTAFNTBPGGT1B | |
| SCHEMBL15124462 | 0.79 | FNTA (0.41) | FNTAFNTBPGGT1B | |
| SCHEMBL20313968 | 0.74 | MTNR1A (0.54) | CKS1BSKP1SKP2 | |
| SCHEMBL8399559 | 0.74 | MAPT (0.54) | CKS1BSKP1SKP2 | |
| SCHEMBL28560594 | 0.74 | ALDH1A1 (0.48) | — | |
| SCHEMBL4897001 | 0.73 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL15125039 | 0.72 | FNTA (0.69) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040563-B2 | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | YALE UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | UNIVERSITY OF WASHINGTON (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | AKR1C3, NR1H3, HCCS | FNTA 18/4885FNTB 38/4885PGGT1B 912/4885 |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | FNTA, FNTB, GDI1 | FNTA 1/4885FNTB 2/4885PGGT1B 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.